Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
OBJECTIVE
Long-term prostate cancer specific mortality after radical prostatectomy is poorly defined in the era of widespread screening. An understanding of the treated natural history of screen detected cancers and the pathological risk factors for prostate cancer specific mortality are needed for treatment decision making.


METHODS
Using Fine and Gray competing risk regression analysis we modeled clinical and pathological data, and followup information on 11,521 patients treated with radical prostatectomy at a total of 4 academic centers from 1987 to 2005 to predict prostate cancer specific mortality. The model was validated on 12,389 patients treated at a separate institution during the same period. Median followup in the modeling and validation cohorts was 56 and 96 months, respectively.


RESULTS
The overall 15-year prostate cancer specific mortality rate was 7%. Primary and secondary Gleason grade 4-5 (each p<0.001), seminal vesicle invasion (p<0.001) and surgery year (p=0.002) were significant predictors of prostate cancer specific mortality. A nomogram predicting 15-year prostate cancer specific mortality based on standard pathological parameters was accurate and discriminating with an externally validated concordance index of 0.92. When stratified by patient age at diagnosis, the 15-year prostate cancer specific mortality rate for pathological Gleason score 6 or less, 3+4, 4+3 and 8-10 was 0.2% to 1.2%, 4.2% to 6.5%, 6.6% to 11% and 26% to 37%, respectively. The 15-year prostate cancer specific mortality risk was 0.8% to 1.5%, 2.9% to 10%, 15% to 27% and 22% to 30% for organ confined cancer, extraprostatic extension, seminal vesicle invasion and lymph node metastasis, respectively. Only 3 of 9,557 patients with organ confined, pathological Gleason score 6 or less cancer died of prostate cancer.


CONCLUSIONS
Poorly differentiated cancer and seminal vesicle invasion are the prime determinants of prostate cancer specific mortality after radical prostatectomy. The prostate cancer specific mortality risk can be predicted with remarkable accuracy after the pathological features of prostate cancer are known.
Section of Urology, University of Chicago Medical Center, Chicago, Illinois, USA.
Scott E
SE
Eggener
Peter T
PT
Scardino
Patrick C
PC
Walsh
Misop
M
Han
Alan W
AW
Partin
Bruce J
BJ
Trock
Zhaoyong
Z
Feng
David P
DP
Wood
James A
JA
Eastham
Ofer
O
Yossepowitch
Danny M
DM
Rabah
Michael W
MW
Kattan
Changhong
C
Yu
Eric A
EA
Klein
Andrew J
AJ
Stephenson
D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D049451:Nomograms; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000601:surgery*; D013997:Time Factors
J Clin Oncol. 2009 Sep 10;27(26):4300-5
19636023
J Urol. 2009 Mar;181(3):956-62
19167731
Br J Cancer. 2006 Nov 6;95(9):1186-94
17077805
J Clin Oncol. 2010 Jan 1;28(1):126-31
19917860
Urol Clin North Am. 2001 Aug;28(3):555-65
11590814
N Engl J Med. 2008 Mar 20;358(12):1250-61
18354103
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
19276453
J Clin Oncol. 2007 Sep 20;25(27):4178-86
17878474
Urology. 2005 Nov;66(5 Suppl):83-94
16194712
J Urol. 2006 Aug;176(2):569-74
16813891
J Urol. 2003 Dec;170(6 Pt 1):2292-5
14634399
Am J Surg Pathol. 2005 Sep;29(9):1228-42
16096414
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
JAMA. 1982 May 14;247(18):2543-6
7069920
JAMA. 2005 May 4;293(17):2095-101
15870412
J Clin Oncol. 2007 May 20;25(15):2035-41
17513807
J Clin Oncol. 2005 Oct 1;23(28):7005-12
16192588
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54
18695132
JAMA. 2004 Jun 9;291(22):2713-9
15187052
N Engl J Med. 2004 Jul 8;351(2):125-35
15247353
J Natl Cancer Inst. 2007 Aug 1;99(15):1171-7
17652279
J Clin Oncol. 2005 Oct 1;23(28):6992-8
16192586
N Engl J Med. 1999 Dec 9;341(24):1781-8
10588962
JAMA. 2005 Jul 27;294(4):433-9
16046649
JAMA. 2008 Jun 18;299(23):2760-9
18560003